Olson DJ, Liu BA, Younan P, Blahnik-Fagan G, et al. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. Cell Rep Med 2026;7:103021.
PMID: 42685702